Strides Pharma Gets USFDA VAI Status for Bengaluru Facility

BENGALURU — Pharmaceutical major Strides Pharma Science Limited announced on Wednesday, August 19, 2026, that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its flagship manufacturing facility located in Bengaluru.

The US health regulator classified the inspection outcome as Voluntary Action Indicated (VAI), marking the successful closure of the regulatory review. The designation follows a comprehensive cGMP (current Good Manufacturing Practices) inspection conducted earlier this year, during which the company successfully addressed observations through prompt corrective and preventive actions.

Regulatory Closure and Manufacturing Compliance

The Bengaluru complex serves as Strides Pharma Science's primary manufacturing hub, producing finished dosage formulations across multiple formats—including tablets, capsules, and specialized liquids—for highly regulated markets across the United States, Europe, and Australia.

According to official corporate filings, regulatory exchange notifications, and company disclosures:

• Inspection Classification: The USFDA classified the facility review as Voluntary Action Indicated (VAI), indicating that while certain observations were noted during the audit, the agency is satisfied with the corrective measures taken.

• EIR Issuance: Receipt of the Establishment Inspection Report formally concludes the audit cycle, clearing regulatory roadblocks for ongoing product approvals and commercial shipments.

• Remediation Efforts: Management highlighted that all audit observations were addressed through targeted quality enhancements, robust laboratory testing protocols, and upgraded electronic data management controls.

• Global Export Readiness: The successful clearance ensures uninterrupted supply chains and manufacturing continuity for the company's export portfolio destined for Western markets.

Official Sources Section

• BSE India Corporate Disclosures: Official material event notifications, regulatory filings, and compliance updates submitted by Strides Pharma Science Limited (BSE: SRID.NS).

• National Stock Exchange of India (NSE): Exchange reporting archives regarding USFDA inspection outcomes and statutory filings.

• U.S. Food and Drug Administration (USFDA): Regulatory guidance, inspection databases, and establishment inspection standards.

Quote Section

According to statements released by Strides Pharma Science corporate executives regarding the inspection closure:

"The successful classification of our Bengaluru flagship facility reflects our unwavering commitment to stringent global quality standards, regulatory compliance, and manufacturing excellence across all our operations."

Why It Matters

For institutional investors, healthcare stakeholders, and international patients, obtaining a clean VAI classification and EIR from the USFDA removes regulatory uncertainty surrounding a critical export facility. Maintaining unhindered access to the U.S. pharmaceutical market protects revenue streams and reinforces corporate confidence in domestic manufacturing capabilities.

Key Facts at a Glance

• Company Name: Strides Pharma Science Limited (SRID.NS).

• Facility Location: Bengaluru, Karnataka.

• Regulatory Agency: United States Food and Drug Administration (USFDA).

• Inspection Outcome: Voluntary Action Indicated (VAI) with official EIR issuance.

FAQ Section

What does the USFDA's VAI classification mean for Strides Pharma? A Voluntary Action Indicated (VAI) classification means that although USFDA inspectors noted certain observations, the agency found the company's corrective actions satisfactory and requires no mandatory regulatory sanctions.

Which facility received the USFDA inspection report? The regulatory clearance applies to Strides Pharma Science's flagship finished-dosage manufacturing facility located in Bengaluru.

How does this impact the company's export operations? The receipt of the Establishment Inspection Report (EIR) ensures uninterrupted manufacturing and smooth export shipments to regulated markets like the United States, Europe, and Australia.

Where can investors verify official regulatory filings? Official stock exchange disclosures and regulatory updates are published directly on the BSE and NSE corporate portals.

Source: BSE India, NSE India, USFDA, Business Standard